Pharmaceutical R&D is at an inflection point. Consider that small molecules accounted for 65% of FDA novel drug approvals in 2025. That is a jump from 56% in both 2023 and 2024. The note that even as biologic sales are growing three times faster than their chemical counterparts and are projected to overtake them by…
Deep Genomics announces key hires, expands operations in Cambridge, Mass.
Deep Genomics, a Toronto-based techbio company founded in 2014, recently opened a new office and lab in Cambridge, Massachusetts, an expansion of its Toronto office, and several leadership hires. The company, which has more than 100 employees with a background in areas spanning AI, automation, molecular biology, clinical development and software engineering, aims to develop…

